$216 Million is the total value of RP Management, LLC's 3 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | BIOHAVEN PHARMACTL HLDG CO L | $167,967,000 | +3.7% | 1,111,111 | 0.0% | 77.60% | +21.4% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $48,462,000 | +19.1% | 3,846,154 | 0.0% | 22.39% | +39.3% | |
| VIRX | VIRACTA THERAPEUTICS INC | $16,000 | -11.1% | 3,700 | 0.0% | 0.01% | 0.0% | |
| Exit | EPIZYME INCcall | $0 | – | -2,575,450 | -100.0% | -1.50% | – | |
| EPZM | Exit | EPIZYME INC | $0 | – | -31,841,394 | -100.0% | -18.49% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOHAVEN PHARMACTL HLDG CO L | 16 | Q3 2022 | 77.6% |
| EPIZYME INC | 11 | Q2 2022 | 44.1% |
| EPIZYME INC | 11 | Q2 2022 | 13.9% |
| VIRACTA THERAPEUTICS INC | 11 | Q3 2023 | 5.7% |
| CYTOKINETICS INC | 10 | Q1 2021 | 7.6% |
| SUNESIS PHARMACEUTICALS INC | 9 | Q4 2020 | 0.1% |
| IMMUNOMEDICS INC | 8 | Q3 2020 | 55.7% |
| BIOCRYST PHARMACEUTICALS INC | 8 | Q3 2023 | 52.0% |
| BIOHAVEN LTD | 4 | Q3 2023 | 73.7% |
View RP Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CYPRESS BIOSCIENCE INC | December 23, 2010 | 3,815,000 | 9.9% |
View RP Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 4 | 2022-08-16 |
| 13F-HR | 2022-08-10 |
| 4 | 2022-05-19 |
| 13F-HR | 2022-05-11 |
View RP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.